Project Grant HT94252410451
- The Department of Defense's Defense Health Agency awarded a $1,330,054 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to the Regents of the University of California, San Francisco (UCSF). The grant supports the "CLINICAL VALIDATION AND IMPLEMENTATION OF A HOST-PATHOGEN-BASED DIAGNOSTIC ASSAY FOR EARLY LYME DISEASE AND OTHER TICK-BORNE INFECTIONS" project, with a performance period from July 1, 2024 to June 30, 2027. As a leading academic medical...
- The U.S. Defense Health Agency awarded a $542,500 Project Grant to Worcester Polytechnic Institute (WPI) under the Military Medical Research and Development program (CFDA 12.420) to support a novel in vitro platform to study Borrelia burgdorferi pathogenesis and genetic susceptibility to Lyme disease. The grant, titled "MSHOST: A Novel Human In Vitro Genome-Wide Association Platform to Study B Burgdorferi Pathogenesis and Genetic Susceptibility to Lyme Disease," will be performed...
- This federal Project Grant award of $1,176,645.00, granted by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports the development of a highly accurate proteomic diagnostic assay to identify active Borreliosis (Lyme disease) infection with point-of-need collection technology. The grant recipient, George Mason University, will conduct this research in collaboration with a subcontract to The Johns Hopkins University, which will provide...
- The Defense Health Agency awarded Duke University a $759,627.49 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "ACCELERATED AGING IN GULF WAR ILLNESS: PHENOTYPES, EPIGENETIC BIOMARKERS, AND ASSOCIATIONS WITH GULF WAR EXPOSURES." The project will run from August 1, 2023 to July 31, 2026. Duke University, a top-ranked global research institution, will be the prime awardee and perform the research through its Office of...
- The Defense Health Agency awarded The Johns Hopkins University a $818,750 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "Immune System Disturbances After Borrelia Burgdorferi Infection". The project will take place over 3 years from August 1, 2023 to July 31, 2026. As a leading research university, Johns Hopkins has extensive experience providing biomedical research, public health initiatives, and scientific analysis to...
- The Department of the Army Medical Command awarded a $1,000,000 project grant to Duke University's Office of Research Administration Division under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on June 1, 2024 and running through May 31, 2027, will fund a practical multi-domain risk model of Alzheimer's disease and related dementias for veteran and non-veteran older U.S. adults. The research project aims to improve the health and care of military service...
- This $2,564,517 Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to Duke University in Durham, NC. The award supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Key focus areas include cancer research, neurological disorders, rare diseases, and innovative medical technologies. The research project is expected to span basic,...
- The Department of Defense's Defense Health Agency awarded Duke University a $1,344,946 Project Grant on September 1, 2023 through the Military Medical Research and Development program (CFDA 12.420). This grant supports a 3-year research project titled "Understanding Heterogeneity and Improving the Precision of Prostate Cancer Clinical Outcomes in the Modern Era." The research aims to advance understanding and treatment of prostate cancer, with a focus on improving clinical outcomes for...
- The University of Maryland, College Park was awarded a $1,292,721.00 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "NOVEL SMALL-MOLECULE THERAPEUTICS AGAINST LYME DISEASE". The grant, awarded on September 30, 2025, has an ultimate completion date of September 29, 2028. The University of Maryland, a prominent research institution, will leverage its extensive capabilities in areas such as...
- The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The Defense Health Agency awarded Duke University a $1,255,621 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to develop diagnostic and therapeutic agents targeting Borrelia burgdorferi, the causative agent of Lyme disease. The grant, with a performance period from September 15, 2024 to September 14, 2027, will enable Duke to conduct innovative biomedical research aimed at improving health outcomes for military service members and the broader public. As a leading research institution, Duke University collaborates extensively with government agencies, academic partners, and industry on federally-funded projects across diverse medical disciplines, including cancer, neuroscience, gene therapy, and emerging technologies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.3m | 5/2/24 |